Argenx Archives -

Argenx only recently scored FDA approval for its intravenous anti-neonatal FC receptor (FcRn) antibody Vyvgart for generalised myasthenia

With rivals threatening, Argenx scores key myasthenia gravis win

https://pharmaphorum.com/news/with-rivals-threatening-argenx-scores-key-myasthenia-gravis-win/

Belgian drugmaker UCB says it will be able to file not one but two new drug therapies for

UCB preps filings for another challenger to AZ’s Soliris

https://pharmaphorum.com/news/ucb-preps-filings-for-another-challenger-to-azs-soliris/

UCB has the positive result it was hoping for in its phase 3 trial of anti-neonatal FC receptor

UCB chases after Argenx with FcRN drug for myasthenia gravis

https://pharmaphorum.com/news/ucb-chases-after-argenx-with-fcrn-drug-for-myasthenia-gravis/

Belgian biotech Argenx has lost its development partner for acute myeloid leukaemia antibody cusatuzumab, after Johnson & Johnson

J&J backs out of $1.6bn blood cancer antibody alliance with Argenx

https://pharmaphorum.com/news/jj-backs-out-of-1-6bn-blood-cancer-antibody-alliance-with-argenx/

ARGX-115 is still in preclinical development

AbbVie takes option on Argenx’s cancer immunotherapy

https://pharmaphorum.com/news/abbvie-takes-option-on-argenxs-cancer-immunotherapy/

Argenx